Clinical Trial Update: Randomized,International Multi-center Clinical Trial of RIF Plus RA for Non-high-risk APL [Phase 3]

View source ↗

Summary

A Phase 3 randomized multicenter trial evaluating RIF Plus RA for non-high-risk acute promyelocytic leukemia is in progress, with status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukaemia

Drugs mentioned

• RA (retinoic acid)
• RIF

Snippet

Sponsor: Peking University People's Hospital | Conditions: Acute Promyelocytic Leukaemia | Phase 3 | Status: UNKNOWN